- Efficacy against infection of over 80%
- Efficacy as a stand-alone vaccine against infection by Delta - 70%
- Efficacy in the age group below 60 – over 75%
- Efficacy against hospitalisation and severe disease is even higher
The Russian Direct Investment Fund is inviting independent international researchers and scientific institutions to cooperate on real-world studies of safety and efficacy of coronavirus vaccines, including Sputnik V, Sputnik Light and others.
On the first anniversary of Sputnik V registration official data from leading countries confirms the vaccine’s high safety and efficacy profile.
The safety and efficacy of Sputnik V and Sputnik Light was confirmed by numerous publications in the leading international scientific journals including The Lancet and Vaccines.
The use of adenovirus vector technology for vector vaccines has been gaining momentum since the 1980s, and is safe and effective, which has been proven in multiple studies.
The Gamaleya National Center of Epidemiology and Microbiology is the world’s leading research institution founded in 1891.
The center runs one of the unique “virus libraries” in the world and has its own vaccine production facility. Gamaleya Research Center has recently received an international patent for Ebola vaccine using adenovirus vector.
The vaccine has received a registration certificate from the Russian Ministry of Health and under emergency rules adopted during the COVID-19 pandemic can be used to vaccinate the population in Russia. Sputnik V is one of the three vaccines in the world with efficacy of over 90%. Sputnik V’s efficacy was validated by internationally peer reviewed data published in
Russia is open to international cooperation in combating the global threat of the COVID-19 pandemic and other future epidemics. We are actively cooperating with more than 14 countries producing our vaccine abroad, including India, China, Brazil, Mexico, Egypt, Iran, Italy, South Korea, Argentina, Kazakhstan, the Republic of Belarus, Serbia, Turkey, Vietnam, etc. We are looking forward to new partners willing to join this initiative and help us save lives.